As CTO of EternaTear, Dr. Stone focuses on achieving formulation, clinical, and regulatory milestone. Most recently, Ralph was the VP of Consumer R&D at Alcon where he developed and launched much of the Systane® artificial tear product line. A PhD chemist by training, Ralph has 35 years of ophthalmic R&D experience and is a recognized FDA expert in the field of ophthalmology.